# Retatrutide

> Triple GLP-1/GIP/glucagon agonist in late-stage obesity trials.

Source: https://peptides.cafe/peptide/retatrutide
Category: Metabolic · Incretin
Tag: Weight loss

## Mechanism
A synthetic peptide that simultaneously agonizes GLP-1, GIP, and glucagon receptors. The glucagon component is hypothesized to add energy expenditure on top of the appetite suppression and insulinotropic effects of GLP-1/GIP.

## Research areas
- Obesity and weight loss (Phase 3)
- Type 2 diabetes
- NAFLD/MASH

## Common research protocols
- Weekly subcutaneous trials: Once-weekly subcutaneous escalation in obesity and T2D trials.

## Study summaries
- "Triple-hormone-receptor agonist retatrutide for obesity" — New England Journal of Medicine (2023): Phase 2 trial showed up to ~24% body weight reduction at 48 weeks.

## Considerations
- Investigational; not FDA-approved (Phase 3 ongoing).
- GI side effects common, similar to other incretin therapies.
- Requires physician oversight.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.